CPHI 2026 at a Glance
Get ready for CPHI 2026. LucidQuest’s CPHI 2026 preview highlights key developments in pharma manufacturing, AI-enabled operations, CDMO strategies and supply-chain resilience, helping you identify priority sessions and shape a focused, insight-led agenda.
📅 Build your schedule around the topics that matter most.
📥 Download the CPHI 2026_Preview_by_LucidQuest
Key Pharma Industry Topics
Manufacturing Infrastructure:
Cell and gene therapies, mRNA, ADCs and bispecifics are expected to increase pressure on aseptic processing, scale-up, fill-finish and commercial manufacturing capacity.
CDMO Evolution:
CDMOs are expected to move beyond capacity provision toward development, technology transfer and strategic innovation partnerships.
Supply-Chain Resilience:
API security, localisation, diversification and local-for-local manufacturing are set to remain central as pharma reassesses supply continuity and geopolitical exposure.
GLP-1 Scale-Up:
Growth in GLP-1 and peptide medicines could reshape manufacturing capacity, oral and injectable formats, drug delivery and supply-chain economics.
Competitor and industry signals from CPHI 2026
- Thermo Fisher Scientific: The programme will connect CDMO strategy, AI-enabled manufacturing, scale-up, technology transfer and GLP-1 execution.
- Fujifilm: Its presence is set to focus on translating cell and gene therapy, mRNA, ADCs and bispecifics into scalable manufacturing and commercial delivery.
- Catalent: Supply resilience, API security, formulation and sustainability are expected to connect ingredient capabilities with broader continuity strategies.
- Datwyler: Packaging and delivery requirements for GLP-1s, biologics and self-administered therapies are set to feature prominently.
Artificial Intelligence and Machine Learning at CPHI 2026
Agentic AI
Sessions are expected to examine how AI agents could support more complex pharmaceutical workflows beyond conventional AI tools.
AI-Ready GxP
Intelligent batch records, AI management systems and predictive manufacturing will put governance, data foundations and validation at the centre of enterprise adoption.
What we’re watching after CPHI 2026
- Whether AI moves from proof-of-concept projects into validated, production-scale pharma workflows.
- Whether manufacturing infrastructure keeps pace with increasingly complex modalities.
- Whether CDMOs increasingly compete on innovation and development capability, not capacity alone.
- How GLP-1 demand changes manufacturing, formulation, delivery and supply-chain models.
📅 Build your schedule around the sessions that matter most.
📥 Download the CPHI 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
